Short Interest in BioSig Technologies, Inc. (NASDAQ:BSGM) Declines By 51.5%

BioSig Technologies, Inc. (NASDAQ:BSGM) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 223,800 shares, a decline of 51.5% from the May 15th total of 461,700 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily volume of 985,800 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioSig Technologies stock. Armistice Capital LLC bought a new position in BioSig Technologies, Inc. (NASDAQ:BSGM) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,600,000 shares of the company’s stock, valued at approximately $2,660,000. Armistice Capital LLC owned about 62.36% of BioSig Technologies as of its most recent SEC filing. 7.16% of the stock is currently owned by hedge funds and other institutional investors.

BioSig Technologies Stock Up 13.9 %

NASDAQ BSGM traded up $0.05 during trading hours on Friday, hitting $0.45. The company had a trading volume of 191,948 shares, compared to its average volume of 449,832. BioSig Technologies has a 52 week low of $0.20 and a 52 week high of $15.50. The firm has a 50 day simple moving average of $1.54 and a 200 day simple moving average of $1.84.

BioSig Technologies (NASDAQ:BSGM) last released its quarterly earnings data on Monday, May 20th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.01 million for the quarter.

BioSig Technologies Company Profile

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.